Please login to the form below

Not currently logged in
Email:
Password:

Merck and Co

This page shows the latest Merck and Co news and features for those working in and with pharma, biotech and healthcare.

Roche’s Tecentriq combo scores FDA approval for melanoma

Roche’s Tecentriq combo scores FDA approval for melanoma

Levi Garraway, Roche’s Genentech division’s chief medical officer and head of global product development. ... However, Roche is likely to face fierce competition from rival checkpoint inhibitors, namely Merck &Co’s Keytruda (pembrolizumab) and

Latest news

More from news
Approximately 43 fully matching, plus 494 partially matching documents found.

Latest Intelligence

  • AI: the smart money is on the smart thinking AI: the smart money is on the smart thinking

    Bayer and Merck &Co provide a perfect example of this. They have developed an AI software system to support clinical decision-making of chronic thromboembolic pulmonary hypertension (CTEPH) – a rare form ... Bayer and Merck &Co hope that radiologists

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    like Novartis, Amgen, Pfizer and Merck &Co/MSD. ... which adds to previous collaborations with Roche’s Genentech subsidiary, Pfizer, and also Merck &Co/MSD that committed $434m to the company shortly after it launched in 2013.

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    Ex-Merck &Co. scientist Joshua Boger did want the company to pioneer rationale drug discovery and development, however, and after. ... a loss in almost all of its 20+ years, and has cumulative net losses of around $3bn.

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases? ... The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    EvaluatePharma forecasts that Lynparza (now co-marketed with Merck &Co) will hit annual revenues of $2.2bn by 2024, with Imfinzi expected to reach $3.65bn and Tagrisso leading the way ... This gives it a unique niche in an IO lung cancer market dominated

More from intelligence
Approximately 0 fully matching, plus 43 partially matching documents found.

Latest appointments

  • Weekly industry appointments Weekly industry appointments

    Laboratories and Merck &Co. ... to help take Abcam to the next stage in its development and growth.”.

  • Nabriva Therapeutics appoints chief medical officer Nabriva Therapeutics appoints chief medical officer

    Schranz. Dr Schranz joins Nabriva from Irish biopharma Shire, with nearly two decades of experience in clinical development and medical affairs. ... Her career has seen her hold positions at Shire, ViroPharma, Pfizer, GlaxoSmithKline and Merck &Co.

  • Hansa Medical poaches Vifor Pharma’s CEO Hansa Medical poaches Vifor Pharma’s CEO

    Tulstrup was most recently CEO of Swiss pharmaceutical group Vifor Pharma and prior to this he served as senior vice president, global franchise head at Shire. ... Additionally, Tulstrup has served as CEO of Santaris Pharma, now part of Roche, and in

  • Astellas promotes Anthony Fiordaliso to VP, Americas finance Astellas promotes Anthony Fiordaliso to VP, Americas finance

    He has been with the pharma company since 2010, when he joined from Schering-Plough (now part of Merck &Co) and subsequently held positions of increasing responsibility. ... In his new role Fiordaliso will report to Stephen Knowles, senior vice president

  • Intellia Therapeutics appoints Dr Moncef Slaoui and Dr Frank Verwiel Intellia Therapeutics appoints Dr Moncef Slaoui and Dr Frank Verwiel

    is establishing a Science and Technology Committee, which will be chaired by Slaoui. ... Verwiel has also served at Merck &Co, where he was vice president and was general manager at Merck Sharpe Dohme’s operations in the Netherlands.

More from appointments
Approximately 4 fully matching, plus 33 partially matching documents found.

Latest from PMHub

  • Practical Patient Centricity

    Merck &Co, Sanofi and UCB have identified the competitive advantage that patient centricity brings and are leading the way in its practical implementation. ... Patient centricity is the next market access – and will take 10 years to embed”.

  • Digital Marketing is no Substitute for Sound Strategic Marketing

    With a stronger market access focus, companies can create and implement stronger marketing strategies. ... With no prior blueprint on how to ‘go digital’ in their marketing, early pioneer companies such as Merck &Co.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics